

# Guy C Toner

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/2333818/publications.pdf>

Version: 2024-02-01

54  
papers

1,876  
citations

331670  
21  
h-index

254184  
43  
g-index

54  
all docs

54  
docs citations

54  
times ranked

2288  
citing authors

#	ARTICLE	IF	CITATIONS
1	Pulmonary function testing for the early detection of drug-induced lung disease: a systematic review in adults treated with drugs associated with pulmonary toxicity. <i>Internal Medicine Journal</i> , 2020, 50, 1311-1325.	0.8	7
2	Online psychological self-management intervention for testicular cancer survivors (e-TC 2.0): promising acceptability and preliminary efficacy, but limited feasibility. <i>Journal of Psychosocial Oncology Research and Practice</i> , 2020, 2, e33.	0.5	4
3	P3BEP (ANZUP 1302): An international randomized phase III trial of accelerated versus standard BEP chemotherapy for adult and pediatric male and female patients with intermediate and poor-risk metastatic germ cell tumors (GCTs).. <i>Journal of Clinical Oncology</i> , 2019, 37, TPS539-TPS539.	1.6	0
4	A systematic review of quantitative observational studies investigating psychological distress in testicular cancer survivors. <i>Psycho-Oncology</i> , 2018, 27, 1129-1137.	2.3	54
5	Protocol for the P3BEP trial (ANZUP 1302): an international randomised phase 3 trial of accelerated versus standard BEP chemotherapy for adult and paediatric male and female patients with intermediate and poor-risk metastatic germ cell tumours. <i>BMC Cancer</i> , 2018, 18, 854.	2.6	7
6	Lutetium-177 PSMA617 theranostics in metastatic castrate-resistant prostate cancer (mCRPC): Interim results of a phase II trial.. <i>Journal of Clinical Oncology</i> , 2018, 36, 5040-5040.	1.6	1
7	P3BEP (ANZUP 1302): An international randomised phase 3 trial of accelerated versus standard BEP chemotherapy for adult and paediatric male and female patients with intermediate and poor-risk metastatic germ cell tumours (GCTs).. <i>Journal of Clinical Oncology</i> , 2018, 36, TPS4596-TPS4596.	1.6	0
8	The utility of genomics and functional imaging to predict Sunitinib PK and PD: The Predict SU study.. <i>Journal of Clinical Oncology</i> , 2018, 36, 2563-2563.	1.6	0
9	The prevalence, severity, and correlates of psychological distress and impaired health-related quality of life following treatment for testicular cancer: a survivorship study. <i>Journal of Cancer Survivorship</i> , 2016, 10, 223-233.	2.9	57
10	Ovarian Growing Teratoma Syndrome With Spuriously Elevated $\beta$ -Fetoprotein. <i>Journal of Clinical Oncology</i> , 2015, 33, e99-e100.	1.6	8
11	The Australian and New Zealand Urogenital and Prostate (ANZUP) Cancer Trials Group: a new cooperative cancer trials group in genitourinary oncology. <i>BJU International</i> , 2015, 115, 856-858.	2.5	0
12	Optimal management of stage I seminoma in 2015. <i>Nature Reviews Urology</i> , 2015, 12, 249-251.	3.8	2
13	Patterns of management and surveillance imaging amongst medical oncologists in Australia for stage I testicular cancer. <i>BJU International</i> , 2013, 112, E35-43.	2.5	14
14	The prevalence and correlates of supportive care needs in testicular cancer survivors: a cross-sectional study. <i>Psycho-Oncology</i> , 2013, 22, 2557-2564.	2.3	65
15	Active Surveillance Is the Preferred Approach to Clinical Stage I Testicular Cancer. <i>Journal of Clinical Oncology</i> , 2013, 31, 3490-3493.	1.6	124
16	Pharmacodynamic analysis of tumour perfusion assessed by 15O-water-PET imaging during treatment with sunitinib malate in patients with advanced malignancies. <i>EJNMMI Research</i> , 2012, 2, 31.	2.5	10
17	Management of Low-stage Nonseminomatous Germ Cell Tumors of Testis: SIU/ICUD Consensus Meeting on Germ Cell Tumors (GCT), Shanghai 2009. <i>Urology</i> , 2011, 78, S444-S455.	1.0	17
18	R1507, a Monoclonal Antibody to the Insulin-Like Growth Factor 1 Receptor, in Patients With Recurrent or Refractory Ewing Sarcoma Family of Tumors: Results of a Phase II Sarcoma Alliance for Research Through Collaboration Study. <i>Journal of Clinical Oncology</i> , 2011, 29, 4541-4547.	1.6	293

#	ARTICLE	IF	CITATIONS
19	Comparison of Two Standard Chemotherapy Regimens for Good-Prognosis Germ Cell Tumors: Updated Analysis of a Randomized Trial. <i>Journal of the National Cancer Institute</i> , 2010, 102, 1253-1262.	6.3	64
20	Gender-specific activity of chemotherapy correlates with outcomes in chemosensitive cancers of young adulthood. <i>International Journal of Cancer</i> , 2009, 125, 426-431.	5.1	31
21	Apical ballooning syndrome during treatment with a vascular endothelial growth factor receptor antagonist. <i>International Journal of Cardiology</i> , 2009, 131, e92-e94.	1.7	22
22	An Open-Label, Single-Arm Phase Two Trial of Gefitinib in Patients With Advanced or Metastatic Castration-Resistant Prostate Cancer. <i>American Journal of Clinical Oncology: Cancer Clinical Trials</i> , 2009, 32, 338-341.	1.3	46
23	Clinical Relevance of "Late" in the Management of Late Relapse After Treatment for a Germ Cell Tumor. <i>Journal of Clinical Oncology</i> , 2008, 26, 5502-5503.	1.6	8
24	Late Relapsing Stage I Nonseminoma. <i>Journal of Clinical Oncology</i> , 2008, 26, 5647-5648.	1.6	4
25	PET for Sarcomas Other Than Gastrointestinal Stromal Tumors. <i>Oncologist</i> , 2008, 13, 22-26.	3.7	32
26	Sustained clinical responses to tyrosine kinase inhibitor sunitinib in thyroid carcinoma. <i>Anti-Cancer Drugs</i> , 2008, 19, 547-552.	1.4	48
27	The Challenge of Poor-Prognosis Germ Cell Tumors. <i>Urologic Clinics of North America</i> , 2007, 34, 187-197.	1.8	1
28	Phase II trial of anti-idiotypic p53 peptides (Pentrys) plus granulocyte-macrophage colony-stimulating factor in patients with hormone-refractory prostate cancer. <i>Asia-Pacific Journal of Clinical Oncology</i> , 2007, 3, 148-155.	1.1	0
29	MANAGEMENT OF MUSCLE-INVASIVE BLADDER CANCER IN VICTORIA, 1990-1995. <i>ANZ Journal of Surgery</i> , 2006, 76, 113-119.	0.7	8
30	ACCURACY OF COMPUTED TOMOGRAPHY GUIDED CORE NEEDLE BIOPSY OF MUSCULOSKELETAL TUMOURS. <i>ANZ Journal of Surgery</i> , 2005, 75, 187-191.	0.7	116
31	MANAGEMENT OF SUPERFICIAL BLADDER CANCER IN VICTORIA: 1990 AND 1995. <i>ANZ Journal of Surgery</i> , 2005, 75, 270-274.	0.7	5
32	Multi-centre Phase II trial of the polyamine synthesis inhibitor SAM486A (CGP48664) in patients with metastatic melanoma. <i>Investigational New Drugs</i> , 2005, 23, 253-256.	2.6	27
33	Clinical applications of molecular imaging in sarcoma evaluation. <i>Cancer Imaging</i> , 2005, 5, 66-72.	2.8	37
34	Durable remissions are rare following high dose therapy with autologous stem cell transplantation for adults with "paediatric" bone and soft tissue sarcomas. <i>International Seminars in Surgical Oncology</i> , 2005, 2, 12.	1.1	5
35	Early Identification of Therapeutic Failure in Nonseminomatous Germ Cell Tumors by Assessing Serum Tumor Marker Decline During Chemotherapy: Still Not Ready for Routine Clinical Use. <i>Journal of Clinical Oncology</i> , 2004, 22, 3842-3845.	1.6	9
36	Improved haematopoietic recovery following transplantation with ex vivo -expanded mobilized blood cells*. <i>British Journal of Haematology</i> , 2004, 126, 536-545.	2.5	39

#	ARTICLE	IF	CITATIONS
37	Gene expression profiling of human colon xenograft tumors following treatment with SU11248, a multitargeted tyrosine kinase inhibitor. <i>Oncogene</i> , 2004, 23, 1618-1626.	5.9	50
38	Hair Depigmentation Is a Biological Readout for Pharmacological Inhibition of KIT in Mice and Humans. <i>Journal of Pharmacology and Experimental Therapeutics</i> , 2003, 307, 476-480.	2.5	80
39	Phase II Trial of Continuous Infusion Carboplatin, 5-Fluorouracil, and Radiotherapy for Localized Cancer of the Esophagus. <i>American Journal of Clinical Oncology: Cancer Clinical Trials</i> , 2002, 25, 277-282.	1.3	9
40	Poor prognosis germ-cell tumors: An unresolved challenge. <i>Urologic Oncology</i> , 2002, 20, 251-261.	1.5	2
41	The management of testicular cancer in Victoria, 1988â€“1993. <i>Medical Journal of Australia</i> , 2001, 174, 328-331.	1.7	14
42	Three and four cycles of bleomycin, etoposide and cisplatin are equivalent in the treatment of good prognosis germ cell cancer. <i>Evidence-based Oncology</i> , 2001, 2, 188-190.	0.1	0
43	Pilot Study of Oral Eniluracil/5-FU in the Palliation of Hormone-Refractory Prostate Cancer. <i>Prostate Journal</i> , 2001, 3, 30-35.	0.2	1
44	A phase I and pharmacokinetic study of paclitaxel and epirubicin in advanced cancer. <i>Investigational New Drugs</i> , 1999, 17, 73-80.	2.6	3
45	Chronic Hiccups Following Chemotherapy. <i>Journal of Pain and Symptom Management</i> , 1999, 18, 387-388.	1.2	4
46	A randomised phase III study of accelerated or standard fraction radiotherapy with or without concurrent carboplatin in inoperable non-small cell lung cancer: final report of an Australian multi-centre trial. <i>Radiotherapy and Oncology</i> , 1999, 52, 129-136.	0.6	140
47	Dose Escalation Study of Carboplatin and Cyclophosphamide With Filgrastim Support. <i>American Journal of Clinical Oncology: Cancer Clinical Trials</i> , 1998, 21, 263-269.	1.3	1
48	Chemotherapy for soft tissue sarcomas. <i>Acta Orthopaedica</i> , 1997, 68, 133-138.	1.4	11
49	Activity of Gemcitabine in Patients with Advanced Ovarian Cancer: Responses Seen Following Platinum and Paclitaxel. <i>Gynecologic Oncology</i> , 1996, 63, 89-93.	1.4	238
50	Extragenital and poor risk nonseminomatous germ cell tumors. Survival and prognostic features. <i>Cancer</i> , 1991, 67, 2049-2057.	4.1	97
51	Sarcoidosis, â€œsarcoid-like lymphadenopathy,â€ and testicular germ cell tumors. <i>American Journal of Medicine</i> , 1990, 89, 651-656.	1.5	31
52	The blood-brain barrier and response of C.N.S. metastases to chemotherapy. <i>Journal of Neuro-Oncology</i> , 1989, 7, 21-24.	2.9	3
53	Lethal skin cancers in hairy cell leukemia (two case reports). <i>European Journal of Haematology</i> , 1987, 39, 82-85.	2.2	5
54	Composite Lymphoma. <i>American Journal of Clinical Pathology</i> , 1986, 86, 375-378.	0.7	22